FDA Clears Second Over-the-Counter Naloxone Spray to Fight Opioid Overdose Crisis

The FDA has approved naloxone hydrochloride (Rextovy; Amphastar Pharmaceuticals), a 4-mg over-the-counter (OTC) nasal spray for the emergency treatment of opioid overdose, expanding consumer access to a life-saving intervention without the need for a prescription. This approval marks the latest effort to increase availability and accessibility to naloxone as the United States continues to confront an opioid epidemic driven largely by illicit synthetic opioids, including fentanyl.¹

Consumers will be able to purchase naloxone hydrochloride nasal spray directly from pharmacies, convenience stores, and online retailers, providing another readily accessible option for overdose reversal. According to the FDA, increasing the number of approved OTC naloxone products may improve market competition, expand supply, and potentially reduce barriers related to cost and availability.¹

Naloxone and Its Role in Opioid Overdose

Naloxone is an opioid antagonist that rapidly reverses the effects of opioid overdose by displacing opioids from receptors in the central nervous system. The medication can restore normal breathing in individuals experiencing respiratory depression caused by opioid exposure and has become the standard of care for emergency overdose treatment.²

The FDA first approved an OTC naloxone nasal spray in 2023, representing a major shift in overdose prevention efforts by allowing consumers to obtain the medication without a prescription. Since then, public health agencies, pharmacists, and community organizations have emphasized broader naloxone distribution as a critical harm-reduction strategy.^2,3

Naloxone hydrochloride nasal spray contains the same active ingredient used in other naloxone nasal spray products and is administered intranasally. The product packaging includes step-by-step pictorial instructions designed for use by individuals without medical training. The instructions emphasize how critical it is to call emergency medical services after administration of the first dose, as naloxone's duration of action may be shorter than that of certain opioids.^1,2

Overdose Deaths Have Declined, But the Crisis Persists

The approval comes amid encouraging but incomplete progress in reducing overdose mortality across the US. According to data cited by the FDA, reported overdose deaths declined from 111,451 during the 12-month period ending in August 2023 to 68,632 during the 12-month period ending in December 2025.¹

Despite these improvements, overdose remains a major public health concern. Synthetic opioids, particularly illicitly manufactured fentanyl and related substances, continue to account for the majority of overdose deaths nationwide. Public health experts have repeatedly identified naloxone accessibility as a key intervention capable of preventing fatal overdoses and reducing mortality in communities disproportionately affected by opioid use disorder.^2,4

In a statement accompanying the approval, FDA officials emphasized the importance of immediate access to naloxone during overdose emergencies and reiterated the agency's commitment to expanding nonprescription treatment options.¹

Safety and Administration Considerations

Naloxone hydrochloride nasal spray is intended for emergency use when an opioid overdose is known or suspected. Following administration and successful reversal of overdose symptoms, individuals may experience acute opioid withdrawal manifestations such as shaking, sweating, nausea, vomiting, irritability, or agitation.^1,2

Naloxone can be administered even when it is uncertain whether opioids are present in an individual's system. Because the medication has no pharmacologic effect in the absence of opioids, experts recommend erring on the side of treatment when overdose is suspected.^1,2

As with other naloxone products, emergency medical services should be contacted immediately after administration, and additional doses may be required if symptoms return or fail to improve.²

Although overdose mortality has declined in recent years, the continuing presence of fentanyl and other synthetic opioids underscores the need for broad naloxone accessibility. The FDA's approval of naloxone hydrochloride nasal spray represents another step toward ensuring that life-saving overdose reversal medication is available wherever and whenever it is needed.¹

REFERENCES

1. FDA broadens access to over-the-counter naloxone nasal spray for opioid overdose. FDA. June 16, 2026.https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose

2. Centers for Disease Control and Prevention. Naloxone: life-saving medication for opioid overdose. CDC. Accessed June 2026. https://www.cdc.gov/stop-overdose/caring/naloxone.html

3. FDA approves first over-the-counter naloxone nasal spray. FDA. March 29, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray

4. National Institute on Drug Abuse. Drug overdose death rates and opioid-related mortality trends. Accessed June 2026.https://nida.nih.gov/publications/drugfacts/naloxone?utm_source=chatgpt.com